Johnson & Johnson Says FDA Grants Priority Review To Subcutaneous Amivantamab For Recurrent Or Metastatic Head And Neck Cancer, Citing 42% Overall Response Rate In OrigAMI-4 Study

Johnson & Johnson

Johnson & Johnson

JNJ

0.00
Johnson & Johnson Says FDA Grants Priority Review To Subcutaneous Amivantamab For Recurrent Or Metastatic Head And Neck Cancer, Citing 42% Overall Response Rate In OrigAMI-4 Study
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.